The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | IMS nursing highlights: talquetamab-induced toxicities, QoL tools & psychological impact of MRD
Monica Morris, MSc, RN, Myeloma UK, Edinburgh, UK, shares some of the most exciting abstracts that were shared in one of the Nursing Symposia oral abstracts sessions, including managing oral and skin toxicities induced by talquetamab treatment, patients’ opinions on quality of life (QoL) tools, and the psychological impact of measurable residual disease (MRD) results on patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
